Ionis Pharmaceuticals
IONS
281 hedge funds and large institutions have $3.92B invested in Ionis Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 60 increasing their positions, 118 reducing their positions, and 45 closing their positions.
59% more call options, than puts
Call options by funds: $92.4M | Put options by funds: $58.2M
54% more capital invested
Capital invested by funds: $2.54B → $3.92B (+$1.38B)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
2% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 45
0% less funds holding
Funds holding: 282 → 281 (-1)
49% less repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 118
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$83.7M |
| 2 |
Millennium Management
New York
|
+$50.3M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$22.1M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$20.3M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$45.4M |
| 2 |
State Street
Boston,
Massachusetts
|
-$20.7M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$19.8M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$15M |
| 5 |
ClearBridge Investments
New York
|
-$13.7M |
IONS Hedge Fund Activity: Q3 2016 in Review
281 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q3 2016, worth a combined $3.92B — up 54% from $2.54B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new IONS positions and 45 closed out — a net gain of 1 holder — while 60 added to existing stakes and 118 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $83.7M. The largest seller was AQR Capital Management, cutting an estimated $45.4M.
- 281 institutional investors held Ionis Pharmaceuticals (IONS) as of Q3 2016, down from 282 in Q2 2016.
- Funds reported $3.92B of Ionis Pharmaceuticals stock for Q3 2016, up 54% quarter-over-quarter.
- 46 funds opened new Ionis Pharmaceuticals positions in Q3 2016 and 45 closed out, a net change of +1 holder.
- The largest Ionis Pharmaceuticals buyer in Q3 2016 was Wellington Management Group, an estimated $83.7M added.
- The largest Ionis Pharmaceuticals seller in Q3 2016 was AQR Capital Management, an estimated $45.4M sold.
Based on aggregated 13F filings for Q3 2016.